Boston Scientific Corp.'s income statement, balance sheet and cash flow statement as filed with the SEC (10-K and 10-Q), with the latest fiscal years and quarters. In its latest fiscal year (Dec 31, 2025 · FY), Boston Scientific Corp. reported revenue of $20.1B (+19.9% year on year) and net income of $2.9B (+56.4% year on year).
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net sales | $20.1B | $16.7B | $14.2B | $12.7B |
| Cost of products sold (excluding amortization expense) | $6.2B | $5.3B | $4.3B | $4.0B |
| Gross profit | $13.9B | $11.5B | $9.9B | $8.7B |
| Selling, general and administrative expenses | $6.9B | $6.0B | $5.2B | $4.5B |
| Research and development expenses | $2.1B | $1.6B | $1.4B | $1.3B |
| Royalty expense | $46.0M | $33.0M | $46.0M | $47.0M |
| Amortization expense | $897.0M | $856.0M | $828.0M | $803.0M |
| Intangible asset impairment charges | $46.0M | $386.0M | $58.0M | $132.0M |
| Contingent consideration net expense (benefit) | $18.0M | ($5.0M) | $58.0M | $35.0M |
| Restructuring net charges (credits) | $101.0M | $16.0M | $69.0M | $24.0M |
| Litigation-related net charges (credits) | $194.0M | $0 | ($111.0M) | $173.0M |
| Operating expenses | $10.2B | $8.9B | $7.6B | $7.1B |
| Operating income (loss) | $3.6B | $2.6B | $2.3B | $1.6B |
| Interest expense | ($349.0M) | ($305.0M) | ($265.0M) | ($470.0M) |
| Other, net | $121.0M | ($16.0M) | ($93.0M) | ($38.0M) |
| Income (loss) before income taxes | $3.4B | $2.3B | $2.0B | $1.1B |
| Income tax expense (benefit) | $493.0M | $436.0M | $393.0M | $443.0M |
| Net income (loss) | $2.9B | $1.8B | $1.6B | $698.0M |
| Preferred stock dividends | $0 | $0 | $23.0M | $55.0M |
| Net income (loss) attributable to noncontrolling interests | ($6.0M) | ($8.0M) | ($1.0M) | — |
| Net income (loss) attributable to Boston Scientific common stockholders | $2.9B | $1.9B | $1.6B | $642.0M |
| Net income (loss) per common share — basic | $1.96 | $1.26 | $1.08 | $0.45 |
| Net income (loss) per common share — diluted | $1.94 | $1.25 | $1.07 | $0.45 |
| Basic | 1.5B | 1.5B | 1.5B | 1.4B |
| Diluted | 1.5B | 1.5B | 1.5B | 1.4B |
| Line item | Jun 30, 2026 · Q2 | Mar 31, 2026 · Q1 | Sep 30, 2025 · Q3 | Jun 30, 2025 · Q2 |
|---|---|---|---|---|
| Net sales | $5.4B | $5.2B | $5.1B | $5.1B |
| Cost of products sold (excluding amortization expense) | $1.6B | $1.6B | $1.5B | $1.6B |
| Gross profit | $3.8B | $3.6B | $3.5B | $3.4B |
| Selling, general and administrative expenses | $1.8B | $1.8B | $1.7B | $1.7B |
| Research and development expenses | $554.0M | $516.0M | $514.0M | $526.0M |
| Royalty expense | $12.0M | $12.0M | $12.0M | $14.0M |
| Amortization expense | $233.0M | $232.0M | $225.0M | $225.0M |
| Intangible asset impairment charges | $0 | — | $0 | $46.0M |
| Contingent consideration net expense (benefit) | ($16.0M) | ($30.0M) | $11.0M | ($5.0M) |
| Restructuring net charges (credits) | $8.0M | $3.0M | ($8.0M) | $83.0M |
| Litigation-related net charges (credits) | $76.0M | — | — | — |
| Operating expenses | $2.7B | $2.5B | $2.5B | $2.6B |
| Operating income (loss) | $1.2B | $1.1B | $1.0B | $819.0M |
| Interest expense | ($96.0M) | ($90.0M) | ($87.0M) | ($90.0M) |
| Other, net | ($23.0M) | $151.0M | ($23.0M) | $213.0M |
| Income (loss) before income taxes | $1.1B | $1.2B | $939.0M | $941.0M |
| Income tax expense (benefit) | $155.0M | ($176.0M) | $183.0M | $146.0M |
| Net income (loss) | $905.0M | $1.3B | $755.0M | $795.0M |
| Net income (loss) attributable to noncontrolling interests | ($2.0M) | ($2.0M) | $0 | ($2.0M) |
| Net income (loss) attributable to Boston Scientific common stockholders | $907.0M | $1.3B | $755.0M | $797.0M |
| Net income (loss) per common share — basic | $0.62 | $0.90 | $0.51 | $0.54 |
| Net income (loss) per common share — diluted | $0.61 | $0.90 | $0.51 | $0.53 |
| Basic | 1.5B | 1.5B | 1.5B | 1.5B |
| Diluted | 1.5B | 1.5B | 1.5B | 1.5B |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Cash and cash equivalents | $2.0B | $414.0M | $865.0M | $928.0M |
| Trade accounts receivable, net | $2.9B | $2.6B | $2.2B | $2.0B |
| Inventories | $2.9B | $2.8B | $2.5B | $1.9B |
| Prepaid income taxes | $299.0M | $307.0M | $315.0M | $264.0M |
| Other current assets | $660.0M | $831.0M | $621.0M | $731.0M |
| Total current assets | $8.8B | $6.9B | $6.5B | $5.8B |
| Property, plant and equipment, net | $4.0B | $3.3B | $2.9B | $2.4B |
| Goodwill | $18.3B | $17.1B | $14.4B | $12.9B |
| Other intangible assets, net | $7.0B | $6.7B | $6.0B | $5.9B |
| Deferred tax assets | $3.7B | $3.7B | $3.8B | $3.9B |
| Other long-term assets | $1.9B | $1.8B | $1.5B | $1.5B |
| TOTAL ASSETS | $43.7B | $39.4B | $35.1B | $32.5B |
| Current debt obligations | $299.0M | $1.8B | $531.0M | $20.0M |
| Accounts payable | $1.1B | $960.0M | $942.0M | $862.0M |
| Accrued expenses | $3.2B | $2.8B | $2.6B | $2.2B |
| Other current liabilities | $795.0M | $887.0M | $814.0M | $761.0M |
| Total current liabilities | $5.4B | $6.4B | $4.9B | $3.8B |
| Long-term debt | $11.1B | $9.0B | $8.6B | $8.9B |
| Deferred tax liabilities | $220.0M | $155.0M | $134.0M | $144.0M |
| Other long-term liabilities | $2.4B | $1.9B | $2.0B | $2.0B |
| Preferred stock, $0.01 par value - authorized 50,000,000 shares; 0 shares issued as of December 31, 2025 and 2024 | 0 | 0 | 0 | 0 |
| Common stock, $0.01 par value - authorized 2,000,000,000 shares; 1,746,290,165 shares issued as of December 31, 2025 and 1,737,846,196 shares issued as of December 31, 2024 | 17.0M | 17.0M | 17.0M | 17.0M |
| Treasury stock, at cost - 263,289,848 shares as of December 31, 2025 and 2024 | -2.3B | -2.3B | -2.3B | -2.3B |
| Additional paid-in capital | $21.5B | $21.1B | $20.6B | $20.3B |
| Retained earnings | $5.6B | $2.7B | $819.0M | ($750.0M) |
| Accumulated other comprehensive income (loss), net of tax | ($610.0M) | $275.0M | $49.0M | $269.0M |
| Total stockholders’ equity | $24.2B | $21.8B | $19.3B | — |
| Noncontrolling interests | $239.0M | $233.0M | $248.0M | — |
| Total stockholders’ equity | $24.5B | $22.0B | $19.5B | $17.6B |
| TOTAL LIABILITIES AND EQUITY | $43.7B | $39.4B | $35.1B | $32.5B |
| Line item | Jun 30, 2026 | Mar 31, 2026 | Sep 30, 2025 | Jun 30, 2025 |
|---|---|---|---|---|
| Cash and cash equivalents | $539.0M | $1.5B | $1.3B | $534.0M |
| Trade accounts receivable, net | $3.0B | $3.0B | $2.8B | $2.8B |
| Inventories | $3.2B | $3.1B | $2.9B | $2.9B |
| Prepaid income taxes | $390.0M | $358.0M | $310.0M | $298.0M |
| Other current assets | $760.0M | $729.0M | $701.0M | $613.0M |
| Total current assets | $8.0B | $8.7B | $8.0B | $7.1B |
| Other investments | $2.2B | — | — | — |
| Property, plant and equipment, net | $4.1B | $4.1B | $3.8B | $3.5B |
| Goodwill | $18.6B | $18.5B | $18.2B | $18.1B |
| Other intangible assets, net | $6.9B | $7.1B | $7.2B | $7.3B |
| Deferred tax assets | $3.9B | $4.0B | $3.7B | $3.8B |
| Other long-term assets | $1.4B | $2.1B | $1.8B | $1.9B |
| TOTAL ASSETS | $45.2B | $44.4B | $42.7B | $41.6B |
| Current debt obligations | $1.7B | $41.0M | $483.0M | $480.0M |
| Accounts payable | $1.2B | $1.1B | $1.0B | $962.0M |
| Accrued expenses | $2.8B | $2.5B | $3.0B | $2.8B |
| Other current liabilities | $732.0M | $875.0M | $862.0M | $952.0M |
| Total current liabilities | $6.4B | $4.6B | $5.3B | $5.2B |
| Long-term debt | $10.9B | $11.0B | $11.1B | $11.1B |
| Deferred tax liabilities | $221.0M | $219.0M | $242.0M | $226.0M |
| Other long-term liabilities | $2.5B | $2.5B | $2.4B | $2.4B |
| Preferred stock, $0.01 par value - authorized 50,000,000 shares - 0 shares issued as of June 30, 2026 and December 31, 2025 | 0 | 0 | 0 | 0 |
| Common stock, $0.01 par value - authorized 2,000,000,000 shares - 1,749,917,975 shares issued as of June 30, 2026 and 1,746,290,165 shares issued as of December 31, 2025 | 17.0M | 17.0M | 17.0M | 17.0M |
| Treasury stock, at cost - 303,212,284 shares as of June 30, 2026 and 263,289,848 shares as of December 31, 2025 | -4.3B | -2.3B | -2.3B | -2.3B |
| Additional paid-in capital | $21.7B | $21.6B | $21.4B | $21.2B |
| Retained earnings | $7.8B | $6.9B | $4.9B | $4.1B |
| Accumulated other comprehensive income (loss), net of tax | ($304.0M) | ($398.0M) | ($689.0M) | ($722.0M) |
| Total stockholders’ equity | $24.9B | $25.9B | $23.4B | $22.4B |
| Noncontrolling interests | $242.0M | $240.0M | $236.0M | $235.0M |
| Total equity | $25.2B | $26.1B | $23.6B | $22.7B |
| TOTAL LIABILITIES AND EQUITY | $45.2B | $44.4B | $42.7B | $41.6B |
| Line item | Dec 31, 2025 · FY | Dec 31, 2024 · FY | Dec 31, 2023 · FY | Dec 31, 2022 · FY |
|---|---|---|---|---|
| Net income (loss) | $2.9B | $1.8B | $1.6B | $698.0M |
| Depreciation and amortization | $1.4B | $1.3B | $1.2B | $1.1B |
| Deferred and prepaid income taxes | ($2.0M) | ($70.0M) | ($1.0M) | ($63.0M) |
| Stock-based compensation expense | $299.0M | $266.0M | $233.0M | $220.0M |
| Goodwill and other intangible asset impairment charges | $46.0M | $386.0M | $58.0M | $132.0M |
| Net loss (gain) on investments and notes receivable | ($139.0M) | $79.0M | $59.0M | $1.0M |
| Contingent consideration net expense (benefit) | $18.0M | ($5.0M) | $58.0M | $35.0M |
| Inventory step-up amortization | $132.0M | $51.0M | $6.0M | $32.0M |
| Fixed asset and right-of-use asset impairment | $124.0M | — | — | — |
| Other, net | $42.0M | $74.0M | $73.0M | $125.0M |
| Trade accounts receivable | ($269.0M) | ($351.0M) | ($238.0M) | ($220.0M) |
| Inventories | ($188.0M) | ($228.0M) | ($660.0M) | ($321.0M) |
| Other assets | ($85.0M) | ($126.0M) | $10.0M | ($209.0M) |
| Accounts payable, accrued expenses and other liabilities | $296.0M | $243.0M | $118.0M | ($255.0M) |
| Cash provided by (used for) operating activities | $4.5B | $3.4B | $2.5B | $1.5B |
| Purchases of property, plant and equipment and internal use software | ($876.0M) | ($790.0M) | ($711.0M) | ($588.0M) |
| Payments for acquisitions of businesses, net of cash acquired | ($1.6B) | ($4.6B) | ($1.8B) | ($1.5B) |
| Payments for investments and acquisitions of certain technologies | ($254.0M) | ($280.0M) | ($89.0M) | ($24.0M) |
| Other, net | $84.0M | $20.0M | $30.0M | $70.0M |
| Cash provided by (used for) investing activities | ($2.6B) | ($5.7B) | ($2.6B) | ($2.0B) |
| Payment of contingent consideration previously established in purchase accounting | ($62.0M) | ($131.0M) | ($39.0M) | ($335.0M) |
| Payments for finance leases | ($258.0M) | ($25.0M) | — | — |
| Payments on short-term borrowings | ($1.6B) | ($504.0M) | $0 | ($250.0M) |
| Net increase (decrease) in commercial paper | ($196.0M) | $187.0M | ($4.0M) | ($1.0M) |
| Proceeds from long-term borrowings, net of debt issuance costs | $1.6B | $2.1B | $0 | $3.3B |
| Cash used to net share settle employee equity awards | -131.0M | -87.0M | -56.0M | -53.0M |
| Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans | 282.0M | 230.0M | 182.0M | 136.0M |
| Other, net | $7.0M | — | — | — |
| Cash provided by (used for) financing activities | ($395.0M) | $1.8B | $5.0M | ($548.0M) |
| Effect of foreign exchange rates on cash | $42.0M | ($11.0M) | ($4.0M) | ($9.0M) |
| Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents | $1.5B | ($450.0M) | ($70.0M) | ($1.0B) |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period | $606.0M | $1.1B | $1.1B | $2.2B |
| Cash paid for income taxes, net | $561.0M | $656.0M | $512.0M | $662.0M |
| Cash paid for interest | $319.0M | $250.0M | $259.0M | $450.0M |
| Fair value of contingent consideration recorded in purchase accounting | $258.0M | $29.0M | $273.0M | $0 |
| Noncash transactions related to finance lease obligations | $205.0M | — | — | — |
| Purchase of Property, plant and equipment, net through exchange of right-of-use assets | $119.0M | — | — | — |
| Cash and cash equivalents | $2.0B | $414.0M | $865.0M | — |
| Restricted cash and restricted cash equivalents included in Other current assets | $80.0M | $111.0M | $130.0M | — |
| Restricted cash equivalents included in Other long-term assets | $103.0M | $80.0M | $60.0M | — |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period | $2.1B | $606.0M | $1.1B | $1.1B |
| Line item | Jun 30, 2026 · YTD | Mar 31, 2026 · Q1 | Sep 30, 2025 · YTD | Jun 30, 2025 · YTD |
|---|---|---|---|---|
| Net income (loss) | $2.2B | $1.3B | $2.2B | $1.5B |
| Depreciation and amortization | $706.0M | $351.0M | $1.0B | $661.0M |
| Deferred and prepaid income taxes | ($334.0M) | ($351.0M) | $20.0M | ($49.0M) |
| Stock-based compensation expense | $170.0M | $83.0M | $228.0M | $149.0M |
| Goodwill and other intangible asset impairment charges | $0 | — | $46.0M | $46.0M |
| Net loss (gain) on investments and notes receivable | ($146.0M) | ($158.0M) | ($181.0M) | ($191.0M) |
| Contingent consideration net expense (benefit) | ($46.0M) | ($30.0M) | $11.0M | $0 |
| Inventory step-up amortization | $6.0M | $2.0M | $127.0M | $118.0M |
| Other, net | $63.0M | $27.0M | $22.0M | $72.0M |
| Trade accounts receivable | ($163.0M) | ($117.0M) | ($171.0M) | ($139.0M) |
| Inventories | ($310.0M) | ($177.0M) | ($138.0M) | ($44.0M) |
| Other assets | ($90.0M) | ($109.0M) | ($103.0M) | ($108.0M) |
| Accounts payable, accrued expenses and other liabilities | ($278.0M) | ($512.0M) | $11.0M | ($154.0M) |
| Cash provided by (used for) operating activities | $1.8B | $348.0M | $3.2B | $1.8B |
| Purchases of property, plant and equipment and internal use software | ($372.0M) | ($177.0M) | ($525.0M) | ($344.0M) |
| Payments for acquisitions of businesses, net of cash acquired | ($718.0M) | ($523.0M) | ($1.5B) | ($1.2B) |
| Proceeds from sale of investments and dispositions of certain technologies | $229.0M | — | — | — |
| Payments for investments and acquisitions of certain technologies | ($1.7B) | — | ($180.0M) | ($110.0M) |
| Other, net | $43.0M | $48.0M | $11.0M | $7.0M |
| Cash provided by (used for) investing activities | ($2.5B) | ($591.0M) | ($2.1B) | ($1.6B) |
| Payment of contingent consideration previously established in purchase accounting | ($78.0M) | — | ($62.0M) | ($62.0M) |
| Payments for finance leases | $0 | $0 | ($49.0M) | ($42.0M) |
| Payments on short-term borrowings | ($272.0M) | ($259.0M) | ($1.6B) | ($1.6B) |
| Net increase (decrease) in commercial paper | $1.7B | $0 | ($196.0M) | — |
| Proceeds from long-term borrowings, net of debt issuance costs | $0 | $0 | $1.6B | $1.6B |
| Cash used to net share settle employee equity awards | -88.0M | -85.0M | -128.0M | -123.0M |
| Payments for Repurchase of Common Stock | ($2.0B) | — | — | — |
| Proceeds from issuances of shares of common stock pursuant to employee stock compensation and purchase plans | 86.0M | 81.0M | 262.0M | 147.0M |
| Other, net | $8.0M | $3.0M | ($2.0M) | ($1.0M) |
| Cash provided by (used for) financing activities | ($670.0M) | ($260.0M) | ($211.0M) | ($107.0M) |
| Effect of foreign exchange rates on cash | $1.0M | $0 | $39.0M | $41.0M |
| Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents | ($1.4B) | ($504.0M) | $870.0M | $135.0M |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period | $2.1B | $2.1B | $606.0M | $606.0M |
| Cash and cash equivalents | $539.0M | $1.5B | $1.3B | $534.0M |
| Restricted cash and restricted cash equivalents included in Other current assets | $81.0M | $71.0M | $98.0M | $109.0M |
| Restricted cash equivalents included in Other long-term assets | $133.0M | $119.0M | $103.0M | $98.0M |
| Cash, cash equivalents, restricted cash and restricted cash equivalents at end of period | $753.0M | $1.6B | $1.5B | $741.0M |
Boston Scientific Corp. score and earnings-call analysis · All covered companies
Figures as reported in SEC filings. General information, not investment advice.